PGY2 Hematology/Oncology Resident UCHealth University of Colorado Hospital Denver, Colorado, United States
Poster Abstract: Background Pneumocystis jirovecii pneumonia is a catastrophic infection arising in immunocompromised patients.Brentuximab vedotin is a drug antibody conjugate targeting CD30 and is used to treat patients with Hodgkin’s lymphoma, Non-Hodgkin's Lymphoma and T-cell lymphoma. Co-expression of CD30 on CD4 cells suggests brentuximab vedotin may lead to an immunocompromised state. However, prophylaxis for opportunistic infections is not recommended in the package insert and listed only as a consideration by societal guidelines. Recent literature has reported an incidence of Pneumocystis jirovecii pneumonia exceeding published thresholds for routine prophylaxis. The frequency and clinical significance of Pneumocystis jirovecii pneumonia following brentuximab vedotin administration at our institution remains poorly defined.
Objectives Evaluate overall incidence of Pneumocystis jirovecii pneumonia among patients receiving brentuximab-based chemotherapy regimens and describe patient characteristics associated with increased risk.
Methods Retrospective, single-arm analysis of adult patients receiving brentuximab-based chemotherapy for hematologic malignancy through September 2023. Exclusion criteria include Pneumocystis jirovecii pneumonia prophylaxis while receiving brentuximab and diagnosis of Pneumocystis jirovecii pneumonia greater than six months from the last brentuximab dose. Patient data was extrapolated from UCHealth Epic Electronic Health Records based in Aurora, Colorado. Variables collected include patient demographics, baseline comorbidities and concomitant medications, diagnosis, number of prior treatments, brentuximab line of therapy and doses, steroid exposure, and Pneumocystis jirovecii pneumonia treatment setting, if applicable. Pneumocystis jirovecii pneumonia was defined as clinical diagnosis documented in the electronic health record.
Results, conclusion, and discussion pending.
References (must also be included in final poster): References 1. Alzona M, Jäck HM, Fisher RI, Ellis TM. CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. J Immunol. 1994 Oct 1;153(7):2861-7.
2. Van der Weyden, C., Pileri, S., Feldman, A. et al. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. 7, e603 (2017).
3. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007 Sep;82(9):1052-9.
4. Scheckel C, Abeykoon JP, Childs, DS, Higgins A, Hwang SR, Barreto J, Ansell SM, Bennani NN. PJP pneumonia in brentuximab vedotin recipients. Journal of Clinical Oncology 2022 40:16_suppl, e19533.
5. ADCETRIS [package Insert]. Bothell, WA. Seattle Genetics, Inc. 2011.
6. National Comprehensive Cancer Network. Guidelines for Prevention and Treatment of Cancer-Related Infections. Version 1.2023.
